Endothelial Function and COVID-19

COVID-19 Clinical Trial

Official title:

Assessment of Endothelial Vasodilator Function in COVID-19 Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04525443
• Other study ID #: 20/451
• Status: Completed
• Start date: June 3, 2020
• Est. completion date: February 11, 2021

Study information

• Verified date: February 2021
• Source: Hospital San Carlos, Madrid
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The present study aims to investigate the endothelial vasodilator function in patients with COVID-19

Description:

Coronavirus disease 2019 (COVID-19), secondary to infection by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has caused a global pandemic with significant adverse effects on the health, social and economic systems in different countries of the world.

The entry receptor utilized by SARS-CoV-2 is Angiotensin-Converting Enzyme 2 (ACE-2), localized at the membrane of epithelial and endothelial cells and muscle cells of blood vessels. Hypothetically, this interaction of SARS-CoV-2 with essential elements of the blood vessels may conduct to endothelial dysfunction. In fact, it has been demonstrated several degrees of endothelial compromise in the kidney, small bowel and lungs from histological analysis in fatidic cases.

The pathophysiological mechanisms by which vascular endothelial dysfunction can complicate the evolutionary course of viral infections are of two types:

1. On the one hand, acute endothelial dysfunction can produce ischemic events as a consequence of thrombotic or vasomotor processes. Some of these events are acute coronary syndromes, pulmonary thromboembolism and peripheral angiopathy, all of which have been reported in COVID-19 patients.

2. On the other hand, vascular endothelial dysfunction can trigger or amplify systemic inflammatory reactions leading to multi-organ failure. Vascular hyperpermeability generated by vascular endothelial dysfunction is key in the processes of infiltration of immune cells and in the amplification of the inflammatory response that occurs in the context of the cytokine storm associated with the viral infection. This process contributes to release large amounts of IL 6, IL-1B and TNF alpha by vascular endothelial cells, thus the expression of vascular adhesion molecules.

In this study, the investigators sought to evaluate the status of vascular endothelial function in COVID-19 patients from a non-invasive approach.

The evaluation of systemic vascular endothelial function will be performed non-invasively using peripheral arterial tonometry with EndoPat system (Itamar). It is a technique that determines the endothelial-dependent changes in arterial tone of the vascular network of the index finger of both hands. Using bio-sensors placed on the pad of the index finger of both hands, an assessment of arterial tone is carried out at three stages: 1) at baseline; 2) during an ischemia caused by the inflation of a pressure cuff in one of the arms to occlude the brachial artery for 5 minutes; 3) and in a situation of reactive hyperemia during the recovery of arterial irrigation after deflating the pressure cuff. The arterial tone signals detected by plethysmography at the three described times are converted into digital signals for each arm explored, and the EndoPat software automatically determines the hyperemic vascular response.

To avoid biases in the analysis of systemic vascular endothelial function in COVID-19 patients, the research team led by Dr. Amir Lerman from the Mayo Clinic, Rochester, USA will blindly carry out the analysis of the EndoPat results. For this, the EndoPat study reports will be sent in an analyzable format for each patient included in the study, completely anonymized and at blind fashion with respect to the group that patient belongs, the moment in which EndoPat assessment was made (days from the onset of symptoms in the case of the study group), blinded for the results of blood tests related to inflammation, and for the clinical evolution of the patient.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 110
• Est. completion date: February 11, 2021
• Est. primary completion date: November 11, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Study group No. 1: age = 18 years; COVID-19 confirmed with positive PCR. Availability of informed consent.

• Study group No. 2: age = 18 years; Past SARS-CoV-2 infection demonstrated by PCR and serology.

• Control group: age = 18 years; absence of concurrent or previous SARS-CoV2 infection demonstrated by serology, and absence of acute or chronic diseases related to endothelial dysfunction, mainly acute or chronic infectious or inflammatory processes and known peripheral vascular disease.

Exclusion Criteria:

• Impossibility of performing the endothelial function test.

• Recent puncture of the radial artery (<15 days).

• Hemodynamic instability.

• Unavailability of signed informed consent.

Related Conditions & MeSH terms

• COVID-19

Locations

Country	Name	City	State
Spain	Hospital Clínico San Carlos	Madrid
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Hospital San Carlos, Madrid	Mayo Clinic

Countries where clinical trial is conducted

United States,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Percentage variation of RHI during the evolutionary course of COVID-19.		At baseline and 1-3 months after COVID-19 resolution
Primary	Reactive hyperemia index (RHI)	RHI derived from peripheral arterial tonometry with EndoPat system (Itamar)	Baseline
Secondary	Percentage of COVID-19 patients with impaired endothelial vasodilator function.		Up to 3 months
Secondary	Percentage of non-COVID-19 patients with impaired endothelial vasodilator function.		Baseline